Los Angeles, June 3, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and […]
Los Angeles, May 21, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and
Los Angeles, April 22, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and
Los Angeles, March 31, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune
Los Angeles, February 25, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune
Los Angeles, January 15, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, October 15, 2024 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, July 16, 2024 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, September 25, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, September 5, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Your feedback is very important to us. We will get back to you within 48 hours.
13547 Ventura Boulevard,
Suite 363
Sherman Oaks, CA 91423
For inquiries about access to our investigational medical products outside of clinical trials, please visit our Expanded Access Policy.